Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.

摘要: Twenty-five to thirty percent of patients with node-negative breast cancer are expected relapse following surgery, therefore great efforts have been made identify new prognostic markers that could be useful in defining for additional therapy. The expression MMP-2 and MMP-9 has associated high potential metastasis several human carcinomas including cancer. In the present study we examined value immunoreactive MMP-2/MMP-9 protein 270 consecutive lymph node negative cases who received radical mastectomy or modified mastectomy. Among patients, 211 adjuvant endocrine therapy and/or chemotherapy. Using immunohistochemical assay, found 56.7% resected tumors were positive whereas 59.6% samples MMP-9. χ2 test demonstrated a significant direct association between ( p < 0.001); immunostaining was significantly related higher tumor grade 0.001) larger size p=0.012); p=0.002). univariate analysis, using Cox-proportional hazard model MMP-2, co-expression MMPs (MMP2/MMP9) patients' free survival p=0.016, 0.015 0.013 respectively) but not overall p=0.122, 0.320 0.091 respectively). Log-rank also showed MMP2/MMP9 unfavorable factor survival. subgroup more no treatment than multivariate MMPs, p=0.038, 0.007 each). We concluded factors patients. They might predictive systemic